TRU-SENTIMENT ยท DeltaNeutral
DVA Trading Analysis - 11/19/2026 12:19 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
DVA (DaVita Inc.) at $153.61. True Sentiment Bullish, delta 40-60 call 68% / put 32%, call $33,500 vs put $16,120. RSI 26.2.
- Symbol
- DVA
- Price
- $153.61
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-19 12:19:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From TRUE SENTIMENT OPTIONS data (methodology: Delta 40-60 only):
Call Volume: $33,500.00 (67.50%) Put Volume: $16,120.00 (32.50%) Total: $49,620.00
Sentiment is Bullish with 27 call contracts vs 16 put contracts, 7 call trades vs 2 put trades. Pure directional conviction skews call-heavy despite tiny sample (9 true-sentiment options of 778 analyzed). This contrasts with bearish technicals (RSI oversold, price below SMAs). Option spread recommendation notes: "Divergence detected between technical indicators and options sentiment."
Key Statistics: DVA
Fundamental Snapshot
Valuation
| P/E (trailing) | 12.50 |
| EPS (trailing 12 mo) | $13.86 |
| Market cap | $9.66B |
| Shares outstanding | 62.9M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.04 |
| 52-week low | $101.00 |
| 52-week high | $247.49 |
| Historical volatility | 48.5% |
Ownership & trading
| Institutional ownership | 30.2% |
| Average daily volume | 0.8M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items reflect general knowledge context for DVA (DaVita Inc.) and are separated from the data-driven analysis below:
- DaVita reported steady dialysis patient volume growth in recent quarters, though labor cost inflation remains a margin pressure point.
- Possible Medicare reimbursement rate adjustments for 2027 have been flagged by industry watchers as a key upcoming catalyst.
- Regulatory scrutiny over kidney care consolidation continues, with FTC monitoring large dialysis operators.
- No confirmed near-term earnings date in this context, but historical fiscal year-end is December, with Q4 reporting typically in February.
- Broad healthcare sector rotation has been mixed, with defensive names like dialysis providers seeing relative stability versus biotech.
Context: Headlines suggest fundamental stability but regulatory overhang. This contrasts with the embedded data showing a sharp recent price drop and oversold RSI, while options sentiment is unexpectedly bullish.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
- Trailing P/E is 12.50 with trailing EPS of 13.86, implying a low valuation relative to broader market averages.
- Market cap is 9.66B with 62.90M shares outstanding; no dividend yield (0.00) and no ex-dividend date.
- Beta is 1.04, indicating near-market-level systematic risk.
- 52-week high is 247.49 and 52-week low is 101.00; current price (~162.69) sits well below the annual high.
- Institutional ownership is 30.21%, relatively moderate for a large-cap healthcare name.
- Historical volatility is 48.55%; average volume is 845,000 shares.
- PEG ratio, forward P/E, profit margins, ROE, debt/equity, and free cash flow are null โ not available in data.
- Analyst consensus and target mean price are null; no recommendation key provided.
Fundamentals show a cheap earnings multiple (P/E 12.50) but lack of margin/ROE data limits quality assessment. The low P/E diverges from the weak technical picture (price below SMAs, RSI 26.23), suggesting either market pessimism or unrecorded fundamental deterioration.
Current Market Position
From the embedded data: The daily close on 2026-11-18 was 162.69 after opening at 171.66 and dipping to a low of 161.01. Minute bars show 2026-11-18 opened at 171.66 and trended down; by 2026-11-19 11:50 the last close was 153.61, with intraday range 152.71โ154.04 and volume building to 26,659 at 11:45.
Key observational levels from data: 30-day low 161.01 (tagged 2026-11-18), 30-day high 196.97 (2026-10-29). Bollinger lower band 167.12; SMA_50 181.86. Price is below all major SMAs and below the lower Bollinger band, indicating extended weakness.
Intraday momentum on minute bars is mildly recovering off 152.71 low to 154.04 then 153.61, with rising volume on up bars (11:35โ11:45), but still far below prior session close.
Technical Analysis
Technical Indicators
SMA alignment: Price (162.69) < SMA5 (171.76) < SMA50 (181.86) โ SMA20 (182.59). Bearish stack with no golden cross; SMA5 below SMA20/50 confirms downtrend. RSI 26.23 is oversold (<30) but not reversing. MACD (-3.01) below signal (-2.41) with negative histogram (-0.60) shows bearish momentum. Bollinger Bands: price below lower band (167.12) โ expansion to downside. 30-day range: low 161.01, high 196.97; price near low extreme.
True Sentiment Analysis (Delta 40-60 Options)
From TRUE SENTIMENT OPTIONS data (methodology: Delta 40-60 only):
Call Volume: $33,500.00 (67.50%) Put Volume: $16,120.00 (32.50%) Total: $49,620.00
Sentiment is Bullish with 27 call contracts vs 16 put contracts, 7 call trades vs 2 put trades. Pure directional conviction skews call-heavy despite tiny sample (9 true-sentiment options of 778 analyzed). This contrasts with bearish technicals (RSI oversold, price below SMAs). Option spread recommendation notes: "Divergence detected between technical indicators and options sentiment."
Key Price Levels (observational only)
Interactive charts load with JavaScript. This text is the crawlable summary.